Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their waistlines.

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage of these medications.

The Trump administration announced deals with Novo Nordisk and Eli Lilly to slash weight-loss drug costs. President Trump called the deals "a triumph for American patients."

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.

The founders of Metsera have a battle to buy their company. It would be their second time striking deal gold.

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.

Novo Nordisk stock slid Wednesday after the Danish drugmaker’s third-quarter results missed estimates, and it trimmed its full-year guidance. Notably, sales growth for its blockbuster obesity drug Wegovy keeps slowing in the race against Eli Lilly.